Coen D A Stehouwer Selected Research

Biomarkers (Surrogate Marker)

8/2023	Thinner inner retinal layers are associated with lower cognitive performance, lower brain volume, and altered white matter network structure-The Maastricht Study.
8/2023	Associations of inner retinal layers with risk of incident dementia: An individual participant data analysis of four prospective cohort studies.
1/2023	Retinal Functional and Structural Neural Indices: Potential Biomarkers for the Monitoring of Cerebral Neurodegeneration: The Maastricht Study.
12/2022	Habitual intake of dietary methylglyoxal is associated with less low-grade inflammation: the Maastricht Study.
1/2022	Sedentary behaviour and physical activity are associated with biomarkers of endothelial dysfunction and low-grade inflammation-relevance for (pre)diabetes: The Maastricht Study.
1/2022	Habitual intake of dietary advanced glycation end products is not associated with generalized microvascular function-the Maastricht Study.
1/2022	Extracerebral microvascular dysfunction is related to brain MRI markers of cerebral small vessel disease: The Maastricht Study.
1/2020	Plasma Metabolomics Identifies Markers of Impaired Renal Function: A Meta-analysis of 3089 Persons with Type 2 Diabetes.
1/2020	The endothelial function biomarker soluble E-selectin is associated with nonalcoholic fatty liver disease.
1/2020	Blood pressure variability and microvascular dysfunction: the Maastricht Study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Coen D A Stehouwer Research Topics

Disease

129	Type 2 Diabetes Mellitus (MODY) 01/2024 - 02/2002
79	Cardiovascular Diseases (Cardiovascular Disease) 01/2023 - 04/2002
64	Inflammation (Inflammations) 01/2023 - 03/2002
55	Insulin Resistance 12/2023 - 02/2002
31	Obesity 01/2024 - 03/2002
30	Hypertension (High Blood Pressure) 01/2023 - 04/2002
30	Atherosclerosis 01/2023 - 03/2002
29	Prediabetic State (Prediabetes) 11/2023 - 09/2009
24	Albuminuria 01/2022 - 10/2002
18	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 01/2005
17	Hyperglycemia 01/2023 - 08/2002
15	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2021 - 10/2002
14	Hyperemia 10/2022 - 05/2002
13	Non-alcoholic Fatty Liver Disease 11/2023 - 04/2007
11	Glucose Intolerance 01/2023 - 07/2002
10	Chronic Renal Insufficiency 01/2019 - 01/2007
9	Weight Loss (Weight Reduction) 12/2023 - 01/2018
8	Necrosis 04/2012 - 12/2003
8	Vascular Diseases (Vascular Disease) 04/2010 - 05/2003
7	Overweight 01/2023 - 11/2014
7	Body Weight (Weight, Body) 01/2022 - 12/2002
7	Renal Insufficiency (Renal Failure) 05/2020 - 11/2003
7	Diabetic Nephropathies (Diabetic Nephropathy) 01/2020 - 05/2002
7	Birth Weight (Birth Weights) 03/2015 - 12/2002
7	Chronic Kidney Failure (Chronic Renal Failure) 03/2009 - 09/2002
6	Dementia (Dementias) 08/2023 - 01/2015
6	Diabetes Mellitus 01/2021 - 05/2002
6	Stroke (Strokes) 01/2018 - 05/2006
6	Hyperinsulinism (Hyperinsulinemia) 08/2010 - 05/2002
5	Diabetes Complications 01/2023 - 03/2011
5	Weight Gain 03/2022 - 12/2002
5	Abdominal Obesity 01/2022 - 05/2009
5	Coronary Disease (Coronary Heart Disease) 01/2018 - 09/2003
5	Myocardial Infarction 01/2018 - 05/2006
5	Hyperhomocysteinemia 12/2011 - 09/2002
4	Fatty Liver 03/2023 - 10/2007
4	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2021 - 08/2002
4	Cerebral Small Vessel Diseases 01/2020 - 01/2017
4	Diabetic Angiopathies (Diabetic Angiopathy) 01/2020 - 05/2002

Drug/Important Bio-Agent (IBA)

121	Glucose (Dextrose)FDA LinkGeneric 12/2023 - 04/2002
48	Insulin (Novolin)FDA Link 01/2024 - 03/2002
44	Biomarkers (Surrogate Marker)IBA 08/2023 - 11/2005
34	LipidsIBA 12/2023 - 08/2002
25	Retinaldehyde (Retinal)IBA 08/2023 - 04/2008
25	Advanced Glycation End ProductsIBA 01/2023 - 03/2004
24	C-Reactive ProteinIBA 12/2022 - 04/2002
23	HomocysteineIBA 10/2012 - 02/2002
20	Triglycerides (Triacylglycerol)IBA 01/2022 - 04/2002
18	HDL CholesterolIBA 01/2023 - 04/2002
18	CholesterolIBA 04/2022 - 10/2002
17	Metformin (Glucophage)FDA LinkGeneric 11/2023 - 12/2002
15	Pyruvaldehyde (Methylglyoxal)IBA 01/2023 - 04/2008
13	Antihypertensive Agents (Antihypertensives)IBA 01/2023 - 04/2007
13	SelectinsIBA 10/2022 - 03/2004
12	von Willebrand FactorIBA 01/2022 - 04/2002
11	AlbuminsIBA 01/2018 - 04/2002
11	Immunoglobulin M (IgM)IBA 01/2016 - 08/2002
10	N(6)-carboxymethyllysine (carboxymethyllysine)IBA 01/2023 - 03/2004
10	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2003
10	CreatinineIBA 01/2018 - 04/2002
9	LDL CholesterolIBA 07/2021 - 10/2002
9	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 03/2015 - 04/2002
8	FructoseIBA 11/2023 - 04/2017
8	Complement System Proteins (Complement)IBA 01/2023 - 12/2012
8	E-SelectinIBA 01/2022 - 03/2004
8	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2020 - 05/2008
8	Folic Acid (Vitamin M)FDA LinkGeneric 01/2019 - 09/2002
8	EnzymesIBA 01/2019 - 12/2003
8	AdiponectinIBA 11/2018 - 06/2003
8	AdipokinesIBA 07/2014 - 05/2005
7	pentosidineIBA 10/2021 - 03/2009
7	Acetylcholine (Acetylcholine Chloride)FDA Link 03/2015 - 05/2002
7	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2010 - 05/2002
6	Interleukin-6 (Interleukin 6)IBA 01/2023 - 09/2006
6	Blood Glucose (Blood Sugar)IBA 01/2022 - 05/2012
6	Uric Acid (Urate)IBA 01/2018 - 11/2014
6	Serum Amyloid A Protein (Serum Amyloid A)IBA 03/2015 - 02/2011
6	Nitroprusside (Sodium Nitroprusside)FDA LinkGeneric 03/2015 - 05/2002
5	SodiumIBA 11/2023 - 11/2014
5	Methionine (L-Methionine)FDA Link 03/2023 - 08/2004
5	Complement C3 (C3 Complement)IBA 01/2022 - 04/2011
5	Vitamin D FDA LinkGeneric 12/2020 - 11/2009
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2015 - 02/2006
5	Interleukin-8 (Interleukin 8)IBA 03/2015 - 03/2012
5	N,N-dimethylarginine (asymmetric dimethylarginine)IBA 07/2012 - 09/2003
5	Plasminogen Activator Inhibitor 1IBA 03/2012 - 06/2005
4	Syntex adjuvant formulationIBA 11/2023 - 01/2017
4	Alanine Transaminase (SGPT)IBA 01/2023 - 04/2007
4	3-deoxyglucosoneIBA 01/2023 - 03/2011
4	Glyoxal (Ethanedial)IBA 01/2023 - 01/2020
4	Complement Factor D (Factor D)IBA 01/2023 - 12/2018
4	SaltsIBA 10/2022 - 09/2007
4	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 11/2021 - 02/2003
4	Cystatin CIBA 01/2018 - 01/2015
4	ThrombomodulinIBA 03/2015 - 03/2004
4	Receptor for Advanced Glycation End ProductsIBA 06/2014 - 04/2008
4	Fibrinogen (Factor I)FDA Link 10/2013 - 01/2005

Therapy/Procedure

20	Therapeutics 01/2023 - 12/2002
11	Glycemic Control 12/2023 - 12/2002
4	Lasers (Laser) 10/2022 - 07/2007